CEEnzalutamide MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target. Website: https://www.selleckchem.com/products/MDV3100.html